These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 15363464

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Position emission tomography with or without computed tomography in the primary staging of Hodgkin's lymphoma.
    Hutchings M, Loft A, Hansen M, Pedersen LM, Berthelsen AK, Keiding S, D'Amore F, Boesen AM, Roemer L, Specht L.
    Haematologica; 2006 Apr; 91(4):482-9. PubMed ID: 16585015
    [Abstract] [Full Text] [Related]

  • 3. The role of PET in lymphoma.
    Jhanwar YS, Straus DJ.
    J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
    [Abstract] [Full Text] [Related]

  • 4. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced non-small cell lung cancer.
    Messa C, Ceresoli GL, Rizzo G, Artioli D, Cattaneo M, Castellone P, Gregorc V, Picchio M, Landoni C, Fazio F.
    Q J Nucl Med Mol Imaging; 2005 Sep; 49(3):259-66. PubMed ID: 16172572
    [Abstract] [Full Text] [Related]

  • 5. Use of 18F-FDG positron emission tomography following allogeneic transplantation to guide adoptive immunotherapy with donor lymphocyte infusions.
    Hart DP, Avivi I, Thomson KJ, Peggs KS, Morris EC, Goldstone AH, Linch DC, Ell PJ, Bomanji JB, Mackinnon S.
    Br J Haematol; 2005 Mar; 128(6):824-9. PubMed ID: 15755287
    [Abstract] [Full Text] [Related]

  • 6. PET/CT for the staging and follow-up of patients with malignancies.
    Poeppel TD, Krause BJ, Heusner TA, Boy C, Bockisch A, Antoch G.
    Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
    [Abstract] [Full Text] [Related]

  • 7. [The role of whole body 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in the management of unknown primary tumors].
    Wu ZJ, Zhang YX, Wei H, Jia Q.
    Zhonghua Yi Xue Za Zhi; 2007 Aug 28; 87(32):2253-6. PubMed ID: 18001544
    [Abstract] [Full Text] [Related]

  • 8. PET/CT for therapy response assessment in lymphoma.
    Hutchings M, Barrington SF.
    J Nucl Med; 2009 May 28; 50 Suppl 1():21S-30S. PubMed ID: 19380407
    [Abstract] [Full Text] [Related]

  • 9. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.
    Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, Luminari S, Vitolo U, Sancetta R, Iannitto E, Trentin L, Stelitano C, Tavera S, Biggi A, Castagnoli A, Versari A, Gregianin M, Pelosi E, Torchio P, Levis A.
    Haematologica; 2006 Apr 28; 91(4):475-81. PubMed ID: 16585014
    [Abstract] [Full Text] [Related]

  • 10. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW, Israel O, Postovsky S, Militianu D, Meller I, Zaidman I, Sapir AE, Bar-Shalom R.
    Pediatr Blood Cancer; 2007 Dec 28; 49(7):901-5. PubMed ID: 17252575
    [Abstract] [Full Text] [Related]

  • 11. [The value of integrated PET-CT images in 2 lymphoma patients with skeletal localisations].
    Geerts MC, Quarles van Ufford HM, Kramer MH, van Waes PF, de Klerk JM.
    Ned Tijdschr Geneeskd; 2006 Jan 28; 150(4):204-9. PubMed ID: 16471237
    [Abstract] [Full Text] [Related]

  • 12. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma.
    Tateishi U, Hosono A, Makimoto A, Nakamoto Y, Kaneta T, Fukuda H, Murakami K, Terauchi T, Suga T, Inoue T, Kim EE.
    Ann Nucl Med; 2009 Feb 28; 23(2):155-61. PubMed ID: 19225939
    [Abstract] [Full Text] [Related]

  • 13. Impact of FDG-PET/CT in the management of lymphoma.
    Baba S, Abe K, Isoda T, Maruoka Y, Sasaki M, Honda H.
    Ann Nucl Med; 2011 Dec 28; 25(10):701-16. PubMed ID: 22037934
    [Abstract] [Full Text] [Related]

  • 14. FDG-PET response-adapted therapy: is 18F-fluorodeoxyglucose positron emission tomography a safe predictor for a change of therapy?
    Hutchings M.
    Hematol Oncol Clin North Am; 2014 Feb 28; 28(1):87-103. PubMed ID: 24287070
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. New developments in staging and follow-up of patients with Hodgkin's lymphoma.
    van Spronsen DJ, Veldhuis GJ.
    Neth J Med; 2003 Sep 28; 61(9):278-84. PubMed ID: 14692440
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
    Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L.
    Eur J Haematol; 2007 Mar 28; 78(3):206-12. PubMed ID: 17253974
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas.
    Specht L.
    Semin Radiat Oncol; 2007 Jul 28; 17(3):190-7. PubMed ID: 17591566
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.